ASR Vermogensbeheer N.V. Has $13.96 Million Position in Becton, Dickinson and Company $BDX

Key Points

• ASR Vermogensbeheer N.V. increased its position in Becton, Dickinson and Company by 22.5%, holding 81,070 shares valued at approximately $13.96 million at the end of the 2nd quarter.
• Several major hedge funds, including Vanguard and T. Rowe Price, have also increased their stakes in Becton, Dickinson, reflecting strong institutional support with 86.97% of the company owned by institutional investors.
• Becton, Dickinson reported a quarterly earnings per share of $3.68, beating analyst expectations, and announced a dividend of $1.04 per share with a 2.2% yield.

ASR Vermogensbeheer N.V. boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 22.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 81,070 shares of the medical instruments supplier's stock after purchasing an additional 14,873 shares during the quarter. ASR Vermogensbeheer N.V.'s holdings in Becton, Dickinson and Company were worth $13,964,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of BDX. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Becton, Dickinson and Company by 3.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after acquiring an additional 448,644 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after acquiring an additional 667,957 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Becton, Dickinson and Company by 7.6% during the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after acquiring an additional 312,124 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Becton, Dickinson and Company by 1.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock valued at $707,872,000 after acquiring an additional 37,733 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock valued at $562,036 in the last ninety days. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Up 2.0%

Shares of Becton, Dickinson and Company stock opened at $190.90 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a market capitalization of $54.72 billion, a P/E ratio of 34.33, a P/E/G ratio of 1.51 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock's 50-day simple moving average is $188.71 and its 200 day simple moving average is $188.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a "sector perform" rating and a $211.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.